BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Direclidine readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Direclidine\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06963034-9196@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Direclidine: Phase 3 readout est. (NCT06963034)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia\nEst
 imated primary completion: October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06963034
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105098-9196@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Direclidine: Phase 3 readout est. (NCT07105098)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia\nEst
 imated primary completion: November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07105098
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288320-9196@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Direclidine: Phase 2 readout est. (NCT07288320)
DESCRIPTION:Direclidine\, phase 2.\nStudy: An Assessment of Efficacy\, Safe
 ty\, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder
  With Current Mania\nEstimated primary completion: February 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/direclidine#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07288320
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227818-9196@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Direclidine: Phase 3 readout est. (NCT07227818)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: Efficacy of NBI-
 1117568 in Preventing Relapse in Adults With Schizophrenia\nEstimated prim
 ary completion: July 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/direclidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07227818
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07114874-9196@assetmemo.bio
DTSTAMP:20261121T004046Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Direclidine: Phase 3 readout est. (NCT07114874)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia\nEst
 imated primary completion: December 2031. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07114874
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
